Shionogi & Co. Ltd., of Osaka, Japan, said lusutrombopag (S-888711), an investigational, once-daily, orally administered, small-molecule thrombopoietin receptor agonist, demonstrated superiority to placebo and met the primary and all pre-specified important secondary endpoints in a global phase III study (L-PLUS2) in thrombocytopenia in patients with chronic liver disease undergoing non-emergent invasive procedures.